Business description: Photocure ASA

Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.

Number of employees: 100

Sales by Activity: Photocure ASA

Fiscal Period: December 2021 (NOK) 2022 (NOK) 2023 (NOK) 2024 (NOK) 2025 (NOK)

Commercial Franchise - Hexvix Europe

226M 222M 264M 286M 310M

Commercial Franchise - Cysview North America

125M 151M 179M 202M 220M

Development Portfolio - R&D

1.84M 18.51M 54.44M 35.64M 2.52M

Commercial Franchise - Other Sales

7.72M 2.02M 4.04M 1.86M 333K

Geographical breakdown of sales: Photocure ASA

Fiscal Period: December 2021 (NOK) 2022 (NOK) 2023 (NOK) 2024 (NOK) 2025 (NOK)

United States

125M 149M 176M 202M 217M

Germany

142M 149M 182M 200M 214M

France

29.02M 27.03M 31.4M 33.41M 36.41M

Nordic

31.88M 22.65M 22.39M 22.21M 21.32M

Austria

8.98M 9.5M 12.07M 12.72M 16.13M

Italy

1.7M 4.37M 5.06M 5.51M 5.85M

Benelux

- 4.6M 5.8M 5.69M 5.05M

Other European Countries

4.03M 3.9M 3.02M 4.13M 5.01M

UK

3.45M 2.15M 2.41M 2.46M 4.99M

Rest of World

2.23M 557K 3.22M 1.93M 3.55M

Canada

- 1.74M 2.78M 2.06M 2.67M

Netherlands

5.67M - - - -

Executive Committee: Photocure ASA

Manager TitleAgeSince
Chief Executive Officer - 2018-10-31
Chief Tech/Sci/R&D Officer - 2021-07-31
Human Resources Officer - 2021-01-31
Corporate Officer/Principal - 2024-03-31
Corporate Officer/Principal - 2019-09-30

Composition of the Board of Directors: Photocure ASA

Director TitleAgeSince
Director/Board Member - 2021-12-31
Chairman - 2023-09-26
Director/Board Member - 2024-05-22

Shareholders: Photocure ASA

NameStocks%Valuation
Briarwood Chase Management LLC
20.17 %
5,469,775 20.17 % 28 M kr
SEB Asset Management AB
12.13 %
3,289,328 12.13 % 17 M kr
JPMorgan Chase Bank, NA (UK Investment Management)
2.945 %
798,755 2.945 % 4 M kr
MP Pensjon PK
2.442 %
662,418 2.442 % 3 M kr
1.896 %
514,148 1.896 % 3 M kr

Holdings: Photocure ASA

NameStocks%Valuation
514,1481.9% 3 M $

Company details: Photocure ASA

Photocure ASA

Hoffsveien 4

0275, Oslo

+47 22 06 22 10

http://ww.photocure.no
address Photocure ASA(PHO)

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-6.79%-26.49%-20.94% 118M
+0.33%+5.22%+41.08%+134.36% 1,280B
+1.32%+4.10%+45.83%+92.02% 675B
-0.17%+2.35%+26.49%+112.79% 521B
+1.14%+2.68%+40.80%+71.70% 386B
-0.06%+0.00%+60.68%+43.40% 363B
+1.11%-0.03%+28.96%+60.05% 301B
+0.24%-0.67%+3.45%+38.06% 286B
-0.19%+1.54%+38.99%+75.26% 253B
-1.01%+0.31%+36.22%+124.33% 211B
Average +0.29%-1.13%+29.60%+73.10% 428B
Weighted average by Cap. +0.45%+0.20%+37.95%+96.00%
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Photocure ASA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.95NOK
Average target price
75.00NOK
Spread / Average Target
+78.78%
  1. Stock Market
  2. Stocks
  3. PHO Stock
  4. Company Photocure ASA